A Single-Center Study of Long-Term Effectiveness of Vedolizumab in Anti-TNF Refractory Pediatric Inflammatory Bowel Disease.

JPGN Rep · 2023 · PMC10004749 · PMID 36915867

Europe PMC DOI

hedged sentence

0.5600

closest p · 11.2× alpha

0.5600

boldest claim

The sentences

did not reach statistical significanceP = 0.56not close (p > 0.1)

UC-specific efficacy of vedolizumab did not reach statistical significance compared with CD ( P = 0.56).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.